MedicaidPrior AuthLow impact
LAMZEDE® (velmanase alfa-tycv) (Revised)
Humana·SC · Genetics, Pediatrics, Internal Medicine·Medicaid
Effective date
Jul 1, 2024
We identified it
Jun 24, 2026
Summary
Humana revised their Medicaid prior authorization policy for LAMZEDE® (velmanase alfa-tycv), an enzyme replacement therapy for alpha-mannosidosis. This affects South Carolina Medicaid members requiring treatment for non-central nervous system manifestations of this rare genetic disorder.
Action Required
Review prior authorization requirements for LAMZEDE® (velmanase alfa-tycv) for South Carolina Medicaid patients with alpha-mannosidosis. Ensure documentation confirms diagnosis of alpha-mannosidosis requiring treatment for non-central nervous system manifestations before submitting prior authorization requests. Visit www.humana.com/PAL for specific medical and procedural coding information.